Pertussis Toxin Pretreatment Reveals Differential Effects of Adenosine Analogs on IgE-dependent Histamine and Peptidoleukotriene Release from RBL-2H3 Cells
Overview
Biophysics
Authors
Affiliations
The effects of adenosine (A) and the nonmetabolizable adenosine analogs, N-ethylcarboxamidoadenosine (NECA), L-phenylisopropyladenosine (L-PIA), D-PIA and 2-chloroadenosine (2CHA) were examined on the IgE-dependent mediator release from RBL-2H3 cells, a model for mast-cell function. Adenosine and the adenosine analogs failed to influence mediator release from cells, previously sensitized with monoclonal anti-TNP mouse immunoglobulin E (anti-TNP IgE), when added alone. When added prior to conjugated trinitrophenol-ovalbumin (TNP-OVA), adenosine and the adenosine analogs (10(-8)-10(-4) M) significantly potentiated the release of both histamine (marker for degranulation) and peptidoleukotrienes (LT) (marker for de novo synthesized mediators). The effects were concentration-dependent with the potency order being L-PIA greater than NECA greater than A greater than D-PIA, 2CHA. The stimulatory effect on both histamine and LT release were reversed by prior treatment of the cells with pertussis toxin but not by the purinoceptor antagonists, theophylline and 8-phenyltheophylline, nor adenosine uptake blockers. At higher concentrations (above 10(-5) M), adenosine and adenosine analogs were also inhibitory on LT but not on histamine release. This inhibition was more evident on pertussis-toxin-treated cells in which there was no effect of adenosine or adenosine analogs on histamine release, but a concentration-dependent inhibition of IgE-dependent LT release. These findings demonstrate that adenosine analogs have two distinct mechanisms on mediator release from RBL-2H3 cells; a stimulatory effect on both histamine and LT release, mediated via a pertussis-toxin-sensitive G protein and an inhibitory effect on LT release via a pertussis-toxin-insensitive pathway. An abstract of this work has been published.
G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation.
Kuehn H, Gilfillan A Immunol Lett. 2007; 113(2):59-69.
PMID: 17919738 PMC: 2094129. DOI: 10.1016/j.imlet.2007.08.007.
Apgar J Mol Biol Cell. 1994; 5(3):313-22.
PMID: 8049523 PMC: 301039. DOI: 10.1091/mbc.5.3.313.
Hagmann W Biochem J. 1994; 299 ( Pt 2):467-72.
PMID: 7513514 PMC: 1138295. DOI: 10.1042/bj2990467.